Published ahead of print on April 7, 2006, doi:10.1164/rccm.200512-1922OC
Am. J. Respir. Crit. Care Med., Volume 174, Number 1, July 2006, 84-93
A more recent version of this article appeared on July 1, 2006
Submitted on December 17, 2005
Accepted on April 6, 2006
Procalcitonin-Guidance of Antibiotic Therapy in Community-Acquired Pneumonia - A Randomized Trial
Mirjam Christ-Crain1*, Daiana Stolz2, Roland Bingisser3, Christian Muller4, David Miedinger2, Peter R Huber5, Werner Zimmerli6, Stephan Harbarth7, Michael Tamm2, and Beat Muller1
1 Department of Internal Medicine, University Hospital, Basel, Switzerland; Department of Endocrinology, University Hospital, Basel, Switzerland,
2 Department of Pneumology, University Hospital, Basel, Switzerland,
3 Department of Emergency Medicine, University Hospital, Basel, Switzerland,
4 Department of Internal Medicine, University Hospital, Basel, Switzerland,
5 Department of Clinical Chemistry, University Hospital, Basel, Switzerland,
6 Medical University Clinic, Kantonsspital, Liestal, Switzerland,
7 Division of Hospital Epidemiology, University Hospital, Geneva, Switzerland
* To whom correspondence should be addressed. E-mail: christmj{at}bluewin.ch.
Rationale: In patients with community-acquired pneumonia, guidelines recommend antibiotic treatment for 7 to 21 days. Procalcitonin is elevated in bacterial infections, and its dynamics have prognostic implications.
Objective: To assess procalcitonin guidance for the initiation and duration of antibiotic therapy in community-acquired pneumonia.
Methods: In a randomized intervention trial, 302 consecutive patients with suspected community-acquired pneumonia were included. Data were assessed at baseline, at days 4, 6 and 8 and after 6 weeks.
The control group (n=151) received antibiotics according to usual practice. In the procalcitonin group (n=151), antibiotic treatment was based on serum procalcitonin concentrations as follows: strongly discouraged <0.1µg/L; discouraged <0.25µg/L; encouraged >0.25µg/L; strongly encouraged >0.5µg/L. Primary endpoint was antibiotic use; secondary endpoints were measures of clinical, laboratory and radiographic outcome.
Results: At baseline, both groups were similar with regards to clinical, laboratory and microbiology characteristics, and Pneumonia Severity Index (PSI). Procalcitonin-guidance reduced total antibiotic exposure (relative risk, 0.52; 95 % confidence interval [CI] 0.48-0.55; P<0.001), antibiotic prescriptions on admission (85 versus 99 %; P<0.001) and antibiotic treatment duration (median, 5 versus 12 days; P<0.001) compared to patients treated according to guidelines. After adjustment for PSI, the hazard ratio of antibiotic discontinuation was higher in the procalcitonin group than in the control group (3.2, 95 % CI 2.5 to 4.2). Outcome was similar in both groups with an overall success rate of 83 %.
Conclusions: Procalcitonin-guidance substantially reduces antibiotic use in community-acquired pneumonia. These findings may have important clinical and public-health implications.
Key words: community-acquired pneumonia, antibiotic therapy, procalcitonin
This article has been cited by other articles:

|
 |

|
 |
 
P. Schuetz, W. Zimmerli, and B. Mueller
Procalcitonin-Based Guidelines and Lower Respiratory Tract Infections--Reply
JAMA,
February 3, 2010;
303(5):
419 - 420.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Stijnis, C. van Nieuwkoop, and J. T. van Dissel
Procalcitonin-Based Guidelines and Lower Respiratory Tract Infections
JAMA,
February 3, 2010;
303(5):
418 - 419.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Hunziker, T. Hugle, K. Schuchardt, I. Groeschl, P. Schuetz, B. Mueller, W. Dick, U. Eriksson, and A. Trampuz
The Value of Serum Procalcitonin Level for Differentiation of Infectious from Noninfectious Causes of Fever After Orthopaedic Surgery
J. Bone Joint Surg. Am.,
January 1, 2010;
92(1):
138 - 148.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Stolz, N. Smyrnios, P. Eggimann, H. Pargger, N. Thakkar, M. Siegemund, S. Marsch, A. Azzola, J. Rakic, B. Mueller, et al.
Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study
Eur. Respir. J.,
December 1, 2009;
34(6):
1364 - 1375.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R Menendez, R Martinez, S Reyes, J Mensa, E Polverino, X Filella, C Esquinas, A Martinez, P Ramirez, and A Torres
Stability in community-acquired pneumonia: one step forward with markers?
Thorax,
November 1, 2009;
64(11):
987 - 992.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Schuetz, M. Christ-Crain, R. Thomann, C. Falconnier, M. Wolbers, I. Widmer, S. Neidert, T. Fricker, C. Blum, U. Schild, et al.
Effect of Procalcitonin-Based Guidelines vs Standard Guidelines on Antibiotic Use in Lower Respiratory Tract Infections: The ProHOSP Randomized Controlled Trial
JAMA,
September 9, 2009;
302(10):
1059 - 1066.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. M. Yealy and M. J. Fine
Measurement of Serum Procalcitonin: A Step Closer to Tailored Care for Respiratory Infections?
JAMA,
September 9, 2009;
302(10):
1115 - 1116.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Struck, M. Strebelow, S. Tietz, C. Alonso, N. G. Morgenthaler, J. G. van der Hoeven, P. Pickkers, and A. Bergmann
Method for the Selective Measurement of Amino-Terminal Variants of Procalcitonin
Clin. Chem.,
September 1, 2009;
55(9):
1672 - 1679.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Mertz, M. Koller, P. Haller, M. L. Lampert, H. Plagge, B. Hug, G. Koch, M. Battegay, U. Fluckiger, and S. Bassetti
Outcomes of early switching from intravenous to oral antibiotics on medical wards
J. Antimicrob. Chemother.,
July 1, 2009;
64(1):
188 - 199.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. S Brown
Biomarkers and community-acquired pneumonia
Thorax,
July 1, 2009;
64(7):
556 - 558.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M.-C. Lin, Y.-C. Chen, J.-T. Wu, Y.-C. Ko, and C.-C. Wang
Diagnostic and Prognostic Values of Pleural Fluid Procalcitonin in Parapneumonic Pleural Effusions
Chest,
July 1, 2009;
136(1):
205 - 211.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Lacoma, C. Prat, F. Andreo, and J. Dominguez
Biomarkers in the management of COPD
Eur. Respir. Rev.,
June 1, 2009;
18(112):
96 - 104.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Singanayagam, J.D. Chalmers, and A.T. Hill
Severity assessment in community-acquired pneumonia: a review
QJM,
June 1, 2009;
102(6):
379 - 388.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. L. Lawrence and M. H. Kollef
Antimicrobial Stewardship in the Intensive Care Unit: Advances and Obstacles
Am. J. Respir. Crit. Care Med.,
March 15, 2009;
179(6):
434 - 438.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Briel, P. Schuetz, B. Mueller, J. Young, U. Schild, C. Nusbaumer, P. Periat, H. C. Bucher, and M. Christ-Crain
Procalcitonin-Guided Antibiotic Use vs a Standard Approach for Acute Respiratory Tract Infections in Primary Care
Arch Intern Med,
October 13, 2008;
168(18):
2000 - 2007.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. N. Schwartz
Procalcitonin-Guided Antibiotic Use vs a Standard Approach for Acute Respiratory Tract Infections in Primary Care
Arch Intern Med,
October 13, 2008;
168(18):
2007 - 2008.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Loebinger, A Shoemark, M Berry, M Kemp, and R Wilson
Procalcitonin in stable and unstable patients with bronchiectasis
Chronic Respiratory Disease,
August 1, 2008;
5(3):
155 - 160.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Ewig and T. Welte
CRB-65 for the assessment of pneumonia severity: who could ask for more?
Thorax,
August 1, 2008;
63(8):
665 - 666.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R Menendez, M Cavalcanti, S Reyes, J Mensa, R Martinez, M A Marcos, X Filella, M Niederman, and A Torres
Markers of treatment failure in hospitalised community acquired pneumonia
Thorax,
May 1, 2008;
63(5):
447 - 452.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. MacNee
Update in Chronic Obstructive Pulmonary Disease 2007
Am. J. Respir. Crit. Care Med.,
April 15, 2008;
177(8):
820 - 829.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Nobre, S. Harbarth, J.-D. Graf, P. Rohner, and J. Pugin
Use of Procalcitonin to Shorten Antibiotic Treatment Duration in Septic Patients: A Randomized Trial
Am. J. Respir. Crit. Care Med.,
March 1, 2008;
177(5):
498 - 505.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Kruger, S. Ewig, R. Marre, J. Papassotiriou, K. Richter, H. von Baum, N. Suttorp, T. Welte, and on behalf of the CAPNETZ Study Group
Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes
Eur. Respir. J.,
February 1, 2008;
31(2):
349 - 355.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. J. Martinez
Pathogen-directed Therapy in Acute Exacerbations of Chronic Obstructive Pulmonary Disease
Proceedings of the ATS,
December 1, 2007;
4(8):
647 - 658.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Masia, J. Papassotiriou, N. G. Morgenthaler, I. Hernandez, C. Shum, and F. Gutierrez
Midregional Pro-A-Type Natriuretic Peptide and Carboxy-Terminal Provasopressin May Predict Prognosis in Community-Acquired Pneumonia
Clin. Chem.,
December 1, 2007;
53(12):
2193 - 2201.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Christ-Crain, D. Stolz, S. Jutla, O. Couppis, C. Muller, R. Bingisser, P. Schuetz, M. Tamm, R. Edwards, B. Muller, et al.
Free and Total Cortisol Levels as Predictors of Severity and Outcome in Community-acquired Pneumonia
Am. J. Respir. Crit. Care Med.,
November 1, 2007;
176(9):
913 - 920.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Christ-Crain and B. Muller
Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators
Eur. Respir. J.,
September 1, 2007;
30(3):
556 - 573.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Stolz, A. Stulz, B. Muller, A. Gratwohl, and M. Tamm
BAL Neutrophils, Serum Procalcitonin, and C-Reactive Protein To Predict Bacterial Infection in the Immunocompromised Host
Chest,
August 1, 2007;
132(2):
504 - 514.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. W. Arnold, J. T. Summersgill, A. S. LaJoie, P. Peyrani, T. J. Marrie, P. Rossi, F. Blasi, P. Fernandez, T. M. File Jr., J. Rello, et al.
A Worldwide Perspective of Atypical Pathogens in Community-acquired Pneumonia
Am. J. Respir. Crit. Care Med.,
May 15, 2007;
175(10):
1086 - 1093.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. B. Milbrandt, A. Ishizaka, and D. C. Angus
Update in Critical Care 2006
Am. J. Respir. Crit. Care Med.,
April 1, 2007;
175(7):
638 - 648.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Stolz, M. Christ-Crain, N. G. Morgenthaler, J. Leuppi, D. Miedinger, R. Bingisser, C. Muller, J. Struck, B. Muller, and M. Tamm
Copeptin, C-Reactive Protein, and Procalcitonin as Prognostic Biomarkers in Acute Exacerbation of COPD
Chest,
April 1, 2007;
131(4):
1058 - 1067.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. S. Niederman
Recent Advances in Community-Acquired Pneumonia: Inpatient and Outpatient
Chest,
April 1, 2007;
131(4):
1205 - 1215.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. J. Martinez and J. L. Curtis
Procalcitonin-Guided Antibiotic Therapy in COPD Exacerbations: Closer But Not Quite There
Chest,
January 1, 2007;
131(1):
1 - 2.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Stolz, M. Christ-Crain, R. Bingisser, J. Leuppi, D. Miedinger, C. Muller, P. Huber, B. Muller, and M. Tamm
Antibiotic Treatment of Exacerbations of COPD: A Randomized, Controlled Trial Comparing Procalcitonin-Guidance With Standard Therapy
Chest,
January 1, 2007;
131(1):
9 - 19.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Other articles noted
Evid. Based Med.,
December 1, 2006;
11(6):
191 - 192.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. P. Espana, A. Capelastegui, I. Gorordo, C. Esteban, M. Oribe, M. Ortega, A. Bilbao, and J. M. Quintana
Development and Validation of a Clinical Prediction Rule for Severe Community-acquired Pneumonia
Am. J. Respir. Crit. Care Med.,
December 1, 2006;
174(11):
1249 - 1256.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Muller and M. Tamm
Biomarkers in acute exacerbation of chronic obstructive pulmonary disease: among the blind, the one-eyed is king.
Am. J. Respir. Crit. Care Med.,
October 15, 2006;
174(8):
848 - 849.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
CAP: Guiding Therapy with Procalcitonin Levels?
Journal Watch Infectious Diseases,
July 12, 2006;
2006(712):
6 - 6.
[Full Text]
|
 |
|

|
 |

|
 |
 
R. G. Wunderink
A CAP on Antibiotic Duration.
Am. J. Respir. Crit. Care Med.,
July 1, 2006;
174(1):
3 - 5.
[Full Text]
[PDF]
|
 |
|
Copyright © 2006 American Thoracic Society
|
|
|